These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8595506)

  • 21. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
    Coombs R; Cotton D; Hammer S; Saag M; van der Horst C
    AIDS Clin Care; 1996 Jan; 8(1):1-4. PubMed ID: 11363056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies confirm value of early and combination treatments.
    Vazquez E
    Posit Aware; 1995; VI(6):8. PubMed ID: 11363148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
    Miura T; Goto M; Hosoya N; Odawara T; Kitamura Y; Nakamura T; Iwamoto A
    J Med Virol; 2003 Aug; 70(4):497-505. PubMed ID: 12794710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
    Cooper EC
    AMFAR Rep; 1996 Jan; ():1-5. PubMed ID: 11363617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
    Bruisten SM; Reiss P; Loeliger AE; van Swieten P; Schuurman R; Boucher CA; Weverling GJ; Huisman JG
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1053-8. PubMed ID: 9718120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
    Yerly S; Kaiser L; Baumberger C; Hirschel B; Perrin LH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):358-64. PubMed ID: 7882100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inter-Company Collaboration Combination Trials. Clinical Trial Subcommittee of the Inter-Company Collaboration for AIDS Drug Development.
    Soo W; Nauss-Karol C; Elkins M; Rooney J; Barry DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S92-6. PubMed ID: 7552520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA; Kemp SD; Harrigan PR
    Science; 1995 Aug; 269(5224):696-9. PubMed ID: 7542804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection.
    Piconi S; Trabattoni D; Fusi ML; Milazzo F; Dix LP; Rizzardini G; Colombo F; Bray D; Clerici M
    Antiviral Res; 2000 Jun; 46(3):171-9. PubMed ID: 10867155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral load in peripheral blood mononuclear cells as surrogate for clinical progression.
    Ferre F; Moss RB; Daigle A; Richieri SP; Jensen F; Carlo DJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S51-6. PubMed ID: 7552513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major study shows AZT monotherapy inferior.
    James JS
    AIDS Treat News; 1995 Sep; (no 231):3-4. PubMed ID: 11362867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sequential dideoxycytidine and zidovudine in advanced HIV-1 infection. Phase II study].
    Ruiz-Argüelles GJ; Lagunes-Yannelli B; Mercado-Díaz L
    Rev Invest Clin; 1993; 45(2):145-7. PubMed ID: 8393211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on other antivirals.
    Cheng B
    PI Perspect; 1996 Apr; (no 18):7-8. PubMed ID: 11363513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
    Kappes JC; Saag MS; Shaw GM; Hahn BH; Chopra P; Chen S; Emini EA; McFarland R; Yang LC; Piatak M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):139-49. PubMed ID: 7552477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction.
    Anderson BD; Shirasaka T; Kojima E; Yarchoan R; Mitsuya H
    Antiviral Res; 1994 Dec; 25(3-4):245-58. PubMed ID: 7710271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3TC: the good news and the bad news.
    Cheng B
    PI Perspect; 1995 May; (no 16):4. PubMed ID: 11362426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.